Global Retinal Biologics Market is segmented By Drug Class(VEGF-A Antagonist and TNF-a Inhibitor), By Disease Indication(Macular Degeneration, Diabetic Retinopathy, Uveitis, and Others), By Distribution Channel(Hospital Pharmacy, Pharmacy Stores and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Retinal Biologics Market Overview
(180 pages) Global Retinal Biologics market to grow at a high CAGR Of 6.5% during the forecast period 2023- 2030. The competitive rivalry intensifies with Amgen, Inc., AbbVie Inc.., Novartis International AG, and others operating in the market.
Retinal biologics are drugs that are derived from living organisms or may contain derivatives from living organisms to treat a wide range of retinal disorders. Human eyes are highly delicate and can be affected by the minutest of things. Therefore, its security is of high importance. People across the globe are facing some serious retinal health disorders including diabetic retinopathy, infectious retinitis, age-related macular degeneration, macular edema, retinoblastoma, uveitis, retinal degeneration, retinoschisis, and macular hole.
Retinal Biologics Market Scope
|
Metrics |
Details |
|
Market CAGR |
6.5% |
|
Segments Covered |
By Drug Class, By Disease Indication, By Distribution Channel and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To know more insights Download Sample
Source: DataM Intelligence Analysis (2020)
Retinal Biologics Industry Dynamics
The global retinal biologics market growth is driven by the growing number of cases with ophthalmic disorders causing chronic retinal diseases across the globe is the primary factor driving the market growth.
The rising burden of retinal diseases and increasing diabetic patient population, is expected to drive the growth in the forecast period
The rising burden of retinal diseases and increasing diabetic patient population, increasing R&D activities and the growing number of FDA approvals. There has been a tremendous increase in the diabetic population, across the globe, over the past decade. Several reports and surveys documented a drastic increase in the diabetic population, based on the changing lifestyle and habits. For instance, according to the British Diabetic Association, it is estimated that almost 3.7 million people are living with diabetes in the United Kingdom and the number has doubled in the past two decades. Moreover, around 12.3 million people are at an increased risk of Type 2 diabetes in the United Kingdom, and obesity is the leading cause in the majority of preventable cases.
Increasing prevalence of retinal vein occlusion (RVO) expected to drive the market growth
Increasing prevalence of retinal vein occlusion (RVO) and age-related macular degeneration. RVO is the second most common retinal vascular disorder and is a significant cause of visual impairment. Around 11 million people in the US have some form of age-related macular degeneration. This number is expected to increase to nearly 22 million by 2050. Increasing research and development coupled with collaborative strategies among industry players to develop biologics will boost retinal biologics market size in the forthcoming years. In September 2019, Ocugen, Inc., partnered with CanSino Biologics for development of product based on gene therapy for treatment of inherited retinal diseases. CanSino Biologics will provide all chemistry, manufacturing, & controls development and clinical supplies for the development of Ocugen’s first gene therapy. Similarly, IVERIC Bio partnered with Catalent Biologics for manufacturing products for treating orphan inherited retinal disease. Thus, continuous innovations and spending on R&D will offer robust growth potential to retinal biologics business.
Regulatory obstruction is likely to hinder the market growth
However, strict regulatory policies coupled with adverse effects of biologics will hamper the industry growth over the forecast period.
COVID-19 Impact on Retinal Biologics Market
There is a perception that people with diabetes are at higher risk both of infection and severe disease from COVID-19. People with type 1 diabetes who have glucose values close to target may not be at greater risk of developing COVID-19. Similarly, as evidence accumulates that many people infected with COVID-19 remain asymptomatic it remains uncertain exactly what additional risk pre-existing diabetes poses. Although the risk of contracting COVID-19 may be no greater, viral infections can cause more severe symptoms and complications in people with diabetes. It should also be noted that a number of people with diabetes are at increased risk due to concomitant immunosuppression following solid organ transplantation. These factors hinder the growth of market in the forecast period.
Retinal Biologics Market Segmentation Analysis
Diabetic Retinopathy segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Diabetic retinopathy (DR) is a leading cause of vision-loss globally. According to the International Diabetes Federation, the devastating consequences of diabetes mellitus is set to continue as a result of the predicted increase in prevalence from 463 million in 2019 to 700 million in 2045. Among this diabetic population, the global prevalence of diabetic retinopathy (DR) and diabetic macular edema (DME), for 2019, were 27.0%. The lowest prevalence was in Europe at 20.6% and South East Asia at 12.5% and highest in Africa at 33.8%, Middle East and North Africa 33.8%, and the Western Pacific region at 36.2%.
The most clinically important risk factors for progression to vision loss include duration of diabetes, hyperglycemia, and hypertension. Control of serum glucose and blood pressure have been shown to be effective in preventing vision loss due to DR. Hence, the rising prevalence of DR, along with the growing awareness and concern over it, are expected to drive the segment growth over the forecast period.
The hospital pharmacy are expected to dominate the retinal biologics market during the forecast period
The hospital pharmacy held the largest share in the retinal biologics market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Source: DataM Intelligence Analysis (2020)
Retinal Biologics Market Geographical Penetration
North America region holds the largest market share global retinal biologics market
North America region is dominating the global retinal biologics market accounted for the largest market share in 2020. People with diabetes are at risk for diabetic retinopathy. Diabetic retinopathy is the leading cause of new cases of blindness among adults aged 20 to 74 years in the United States. More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report published by the Centers for Disease Control and Prevention (CDC). In Canada, the prevalence of diabetes among adults is 10.2% and about 3.6 million patients were suffering from diabetes in 2017. Additionally, scientists are investing new ways to treat diabetic macular edema. Thus, growing funding for R&D in the country coupled with risk factors contributing to disease development will influence U.S. retinal biologics market growth in the forecast period.
Source: DataM Intelligence Analysis (2020)
Retinal Biologics Company and Competitive Landscape
The retinal biologics market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Spark Therapeutics, Regeneron Pharmaceuticals, Inc, Novartis International AG, Ocular Therapeutix, Amgen, Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the retinal biologics market globally.
Amgen Inc
Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and market medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
Product Portfolio: The Company’s portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.
Why Purchase the Report?
- Visualize the composition of the retinal biologics market segmentation by drug class, disease indication, distribution channel, and region highlighting the key commercial assets and players.
- Identify commercial opportunities in retinal biologics market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of retinal biologics market - level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global retinal biologics market report would provide an access to an approximately 45+ market data table, 40+ figures and 180 pages.
